Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...

Preclinical research in fruit flies and cell cultures suggests that a dual-targeting drug could help prevent the accumulation ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to ...

Roche's experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion) a year if it clears two key trials on early treatment of the ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Oct 7 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not show superior benefits compared to ...